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Abstract 
The congenital abnormal protein SToku+ma has Glu substituted for Lys”’ in the second epidermal growth fact(, ‘r domain of the protein 
S molecule (Hayashi T., Nishioka J., Shigekiyo, T. Saito, S. and Suzuki, K.(l994) Blood 83, 683-690). To el, ~lcidate the molecular 
mechanism of the dysfunction of the protein STokurhlmar a comparative evaluation between the molecular interact1 ‘on of the abnormal 
protein S and thflt of normal protein S with other clotting factors was carried out using recombinant normal protein s t’rPSN) and Protein 
S Toku,h,,,,e (rPS’T) expressed in baby hamster kidney cells. While rPSN and plasma protein S exhibited cofactor acti\ ‘Ity for activated 
protein C (AP(Z:I, rPST did not show this property. rPSN and rPST bound equally to phospholipids and C4b-binding p, ?otein fixed on 
microplate wells. APC bound to rPSN but not to rPST in an assay using immobilized monoclonal anti-protein S antibody. On the other 
hand, rPSN alld plasma protein S inhibited the activity of prothrombinase complex composed of factor Xa and thrombil l-stimulated 
platelets, wherea[s rPST lacked this inhibitory effect. Assessment of the mechanism by which rPST lacks inhibitory activ,‘ty on the 
platelet-prothrorrlbinase complex was also performed. Factor Xa bound to rPSN but not to rPST. Binding to rPSN to biotinylatt yd factor 
Va in solution pmhase did not differ significantly from that of rPST. Binding of prothrombin to factor Va in solution phase w ‘as not 
inhibited either by rPSN or rPST. Binding of 4-amidinophenylmethanesulfonyl-factor Xa to factor Va in solution phase increased i, q the 
presence of rPSbI but not in that of rPST. These findings suggest that the dysfunction of protein STokuahlma occurs because it fails @ 
interact with APC and factor Xa. This molecular interaction is required for the expression of the APC cofactor activity and for th’e 
inhibition o’f the F)rofhrombinase complex activity. 
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1. Introduction 
Protein S is a plasma vitamin K-dependent glycoprotein 
that serves as a cofactor of the anticoagulant protease, 
activated protein C (APC)’ [l]. In the presence of protein 
S, APC efficient@ inactivates factor Va and factor VIIIa, 
Abbreviations: ‘AMC, 4-amino-7-methylcoumarin; APC, activated 
protein C; aPMS, 4-amidinophenylmethanesulfonyl; APTT, activated par- 
tial thromboplastin time: BSA, bovine serum albumin; C4BP, C4b-bind- 
ing protein; DFP, diisopropyl fluorophosphate; DIP, diisopropyl phos- 
phate: EGF, epidermal growth factor; Gla, y-carboxyglutamic acid; IC,,, 
concentration at half-maximal inhibition; K,, dissociation constant; pNA, 
p-nitroanilide; rPSN, recombinant normal protein S; rPST, recombinant 
protein S, L h ; 0 “I lrn‘l SHBG, sex hormone binding globulin; TBS. Tris- 
buffered saline 
~ Corresponding author. Fax: + 81 592 315209; e-mail: 
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which are essential factors for the catalytic activity of the 
prothrombinase complex and of the tenase complex, re- 
spectively [2,3]. Protein S has been considered to function 
as a receptor of APC on the surface of phospholipids in the 
APC-dependent anticoagulation [4,_5]. Recently, it was re- 
ported that protein S inhibits directly factor Xa activity 
[6,7] and competitively the prothrombin binding to factor 
Va [8]. This inhibitory activity of protein S appears to be 
independent of APC. 
Protein S circulates in human plasma in a free form and 
in a form complexed with the complement component 
C4b-binding protein (C4BP) [9,10]. This C4BP inhibits the 
APC cofactor activity of protein S [ 11,12]. However, both 
forms of protein S are able to bind to APC [ 121 and to 
factor Xa [7]. 
Human protein S [13,14], as well as its counterparts 
from bovine [ 1.51, rabbit [ 161 and rat [ 171 are composed of 
a y-carboxyglutamic acid (Gla)-rich domain, a thrombin- 
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sensitive domain, four consecutive epidermal growth factor 
(EGF) domains, and a sex hormone binding globulin 
(SHBG)-like &main. Previous reports suggested that both 
the G]a-rich domain and the first EGF domain are required 
for expression of the cofactor activity of APC [18]. The 
thrombin-Se!lSitiVe domain may also be required for the 
interaction with phospholipids and for expression of the 
ApC cofstor activity because the thrombin-modified pro- 
tein S iFless active than the intact protein S [5]. Two loop 
stmctues of the COOH-terminal SHBG-like domain and a 
regiol of the COOH-terminal end of protein S were sug- 
gesed to be the interaction sites with C4BP [19,20] and 
f;itor Va [21], respectively. 
Subjects with hereditary protein S deficiency are at high 
risk of suffering from VZ~IOUS thromboembolic disease 
[22,23]. Recently, we reported a study of patients with 
heterozygous protein S deficiency; the proband with severe 
thrombotic disease presented normal protein S antigen, 
both total and free, but IOW APC cofactor activity [24]. 
This dysfunctionnl protein S, termed protein STokuhima, 
shows abnormal electrophoretic mobility and low affinity 
for two monocional anti-protein S antibodies, one of which 
recognizes the Ca’+ -dependent conformation and another 
the thrombic-sensitive domain. It has an A to G mutation 
in which iys”’ is replaced by Glu in the second EGF 
domain 1251. 
In tie present study, we assessed the mechanism by 
which the dysfunction of protein SToku\h,ma occurs by 
comparing the molecular interaction of this abnormal pro- 
ten S and that of normal protein S with phospholipids, 
C4BP, APC, factor Xa and factor Va. The interaction of 
protein S with these clotting factors are required for the 
expression of the APC cofactor activity and for the inhibi- 
tion of the prothrombinase complex activity. Based on our 
results, the binding sites of APC, factor Xa and factor Va 
on the protein S molecule were discussed. 
2. Materials and methods 
Bovine serum albumin (BSA), rabbit brain cephalin that 
is generally used as phospholipid suspension for the coagu- 
lation assay [26], and Russell’s viper venom were obtained 
from Sigma (St. Louis, MO). BrCN-activated Sepharose 
4B and protein A-Sepharose 4B were from Pharmacia 
(Uppsala, Sweden). Chromogenic substrates for APC, Glu- 
Pro-Arg-p-nitroanilide (pNA) (S-2366), and for factor Xa, 
Bz-Ile-Glu-Gly-Arg-pNA (S-2222), were from CHRO- 
MOGENIX (Stockholm, Sweden). The fluorogenic sub- 
strate for thrombin, Boc-Val-Pro-Arg-methylcoumaryla- 
mide (MCA), was from the Protein Research Foundation 
(Osaka, Japan). Diisopropylfluorophosphate (DFP), 
phenylmethylsulfonyl fluoride (PMSF) and 4- 
amidinophenylmethanesulfonyl fluoride were from WAKO 
Pure Chem. (Osaka, Japan). MaxiSorp II microwell plates 
were from Nunc (Roskilde, Denmark). N-hydroxysucci- 
nimido-biotin and streptavidin were from Amersham Inter- 
national plc (Buckinghamshire, UK). All other chemicals 
and reagents used in the present sudy were of the best 
quality commercially available. 
Prothrombin [27], factor X [27], factor V [2], protein C 
[2], protein S [5] and C4BP [lo] were 3urified from normal 
human plasma, as described previously. Thrombin (2000 
U/mg) was purified as described [28]. Thrombomodulin 
was purified from human placenta as described [29]. Factor 
V and protein C were activated by thrombin and 
thrombin-thrombomodulin complex, .espectively 12,291. 
Factor X was activated using Russell’sviper venom-factor 
X activator [30]. When necessary, facto] Xa and APC were 
inactivated by treating with 4-amidnophenylmethane- 
sulfonyl fluoride (aPMS-factor Xa) and DFP (DIP-APC), 
respectively. The M, and absorption cotfficients used for 
the respective proteins were as follows: prothrombin: 
72 000, A& nm = 14.7[31];factorX:59000, A&,.,= 11.6 
[32]; factor V: 330000, A$ nm = 9.6 [33]; protein C: 
62000, A& nm = 13.7 [2]; protein S: 75 030, A$, nm = 9.5 
[IO]. 
2.1. Expression of recombinant protein S 
Expression vectors for recombinant normal protein S 
(rPSN) and recombinant protein STokurtinw (rPST) were 
constructed as described previously [25]. rPSN and rPST 
were expressed in baby hamster kidney (BHK) cells as 
follows: BHK cells were maintained in high glucose Dul- 
becco’s modified Eagle’s medium containing sodium pyru- 
vate and glutamine (GIBCO, Grand Island, NY) and sup- 
plemented with 5% fetal bovine serum (GIBCO), 0.01% 
penicillin, and 0.01% streptomycin (Sank0 Junyaku, Tokyo, 
Japan). Stable cell lines expressing rPSN and rPST were 
obtained using the calcium phosphate ttansfection method 
[34], followed by selection in medium containing 
methotrexate [35]. To purify recombinant protein S, con- 
fluent cells were washed with serum-free medium and then 
overlaid with the same medium without fetal bovine serum 
containing 10 pg/ml vitamin Kl (Nacalai Tesque, Kyoto, 
Japan). The culture medium was collecled 72 h later and 
supplemented with 1 mM benzamidine, 0.1 mM DFP, and 
0.1 mM PMSF. The medium was separated from cell 
debris by centrifugation and frozen at -20°C until purifi- 
cation. 
2.2. Purification of recombinant protein S 
The recombinant protein S expressed in culture medium 
of BHK cells was partially purified as described previously 
[25]. Briefly, the barium-citrate precipitate from the culture 
medium was dissolved in 0.2 M EDTA solution and then 
dialyzed against 0.1 M phosphate buffer (pH 6.0) contain- 
ing 0.1 mM DFP and 0.1 mM PMSF. This sample was 
then subjected to HPLC using a PROTEIN PAK G-QA 
column (Waters, Tokyo, Japan) equilibrated with 0.1 M 
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phosphate buffer (pH 6.0). Ttie fractions containing protein 
S eluted with a linear gradient of NaCl (0 to 0.6 M) were 
pooled and dialyzed against Tris-buffered saline (TBS; 
0.05 M Tris-HCl, 0.1 M NaCl (pH 7.5)) containing 5 mM 
CaCl,. The dialysate was subjected to column chromatog- 
raphy using monoclonal anti-protein S IgG (MFS- 1; which 
did not affect the APC cofactcr activity of protein S 
[25])-coupled Sepharose 4B equihbrated with TBS. After 
washing the column with TBS, tb bound protein S was 
eluted with 8 M urea as described previously 1251. The 
eluate was immediately dialyzed against TBS and stored at 
- 80°C until use. 
mi;ture, 50 ~1 of APTT reagent (Actin; Dade, FL) was 
adled. After 5 min of incubation, 50 ~1 of 25 mM CaCl, 
wds added to the mixture and clotting time was deter- 
nined. 
2.6. Determination of prothrombinase complex activity 
2.3. Preparation of biotinylated factor V and factor Va 
500 ~1 of factor V (270 pg) was mcubated with the 
N-hydroxysuccinimido-biotin (250 pg) in Hepes-buffered 
saline (0.05 M Hepes-NaOH (pH 8.0), 0.1 M NaCl) con- 
taining 2 mM CaCl, at room temperature for 30 min. The 
reaction was then terminated by the addition of IO ~1 of 1 
M Tris solution. The biotinylated factor V was concen- 
trated using Speed-Vat concentrator, and free biotin was 
removed by gel filtration using a PD- 10 column (Phar- 
macia Biotech, Uppsala, Sweden). To prepare biotinylated 
factor Va, the biotinylated factor V was treated with 
thrombin (3.3 U/ml) at 37°C in TBS containing 2 mM 
CaC12. Aliquots were taken at intervals and coagulant 
activity of factor Va was determined by the prothrombi- 
nase complex activity reconstituted using factor Xa and 
phospholipids (cephalin) as described above. After maxi- 
mal factor V activation was achieved, DFP (1 mM final 
concentration) was added. Biotinylated factor Va had the 
same procoagulant activity in the prothrombinase complex 
as the unlabeled factor Va. 
Activation of prothrombin by factor Xa in the presence 
of activated platelets was determined as follows: 40 ~1 of 
a mixture containing thrombin-stimulated gel-filtrated hu- 
man platelets (3.5 . lo5 cells) and 200 nM prothrombin 
were preincubated in TBS containing 0.1% BSA and 2 
mM CaCl, at 37°C for 5 min. Then, 10 ~1 of factor Xa 
il.3 nM final concentration) was added to the mixture. 
After 3 min of incubation, the reaction was terminated by 
adding 10 ~1 of 200 mM EDTA. The amount of thrombin 
generated was determined by the initial rate assay using 2 
ml of 100 FM Boc-Val-Pro-Arg-MCA in TBS containing 
2 mM CaCl,. The fluorescence of the 4-amino-7-methyl- 
coumarin (AMC) was examined by using a spectrofluo- 
rophotometer RF-5 10 (Shimadzu, Kyoto, Japan) with exci- 
tation at 380 nm and emission at 440 nm [36]. Activation 
of prothrombin by factor Xa alone was assessed as fol- 
lows: 40 ~1 of a mixture of prothrombin (200 nM final 
concentration) in TBS containing 0.1% BSA and 2 mM 
CaCl?, was activated by factor Xa (1.3 nM final concentra- 
tion) at 37°C for 2 h in the presence of phospholipids (30% 
cephalin), or for 3 h in the absence of phospholipids, and 
the reaction was terminated by the addition of 10 ~1 of 
200 mM EDTA. 
To determine the effect of protein S on the activation of 
prothrombin by factor Xa, various concentrations of pro- 
tein S were mixed with prothrombin in the reaction solu- 
tion before adding factor Xa. 
2.4. Determination of protein S concentration 2.7. Binding assay of protein S to fixed phospholipids 
Concentration of plasma protein S and recombinant 
protein S in various solutions was determined by the 
sandwich-type enzyme-linked immunosorbent assay using 
polyclonal anti-protein S-F(ab)’ coupled with peroxidase 
and tetramethylbenzidine, according to a method previ- 
ously described [25]. 
2.5. Determination of APC cofactor activity 
APC cofactor activity of rPSN and rPST was deter- 
mined by the activated partial thromboplastin time (APTT) 
test using the Coagulometer KC- 10 (Amelung, 
Lehbrinksweg, Germany), as follows: 100 ~1 of protein S 
solution in TBS was mixed with 50 ~1 of protein S- and 
C4BP-depleted plasma. The latter was prepared through 
two column chromatographies using anti-protein S IgG- 
coupled Sepharose 4B and anti-C4BP IgG-coupled 
Sepharose 4B as previously described [25]. To the above 
Wells of microtiter plates were first coated with 100 ~1 
of cephalin in 0.1 M sodium bicarbonate buffer (pH 9.2). 
After 2 h of incubation, the wells were blocked with 150 
~1 of TBS containing 5% BSA and 1% gelatin for 2 h, 
then washed three times with TBS containing 2 mM 
CaCl,, 0.1% BSA and 0.05% Tween-20. Thereafter, 100 
~1 of various concentrations of protein S in the same 
buffer used for washing were added to the wells and the 
preparations were incubated overnight at room tempera- 
ture. After washing the wells with the same buffer, 100 ,ul 
of polyclonal anti-protein S F(ab)’ coupled with peroxi- 
dase (0.5 pg/ml) was added to the wells followed by 
incubation for 2 h. After washing the wells three times 
with the above buffer, 100 ~1 of freshly prepared tetram- 
ethylbenzidine (0.1 mg/ml) and 0.005% HZOZ in sodium 
acetate buffer (pH 5.5), was added to each well. The 
enzyme reaction was terminated after 30 min by adding 50 
~1 of 1 M sulfuric acid. Absorbance of each well was 
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determined at 450 nm using EAR340 mil-rowell platt: 
reader (SLT-Lab Instruments, Salzburg, Austria), as de- 
scribed [25]. 
2.8. Binding assay of protein S to fixed C4BP 
Microwells were coated with 100 ~1 of C4!BP (10 
pg/ml) in 0.1 M sodium bicarbonate buffer (pry 9.2). 
After incubating for 2 h, the wells were blocked with 150 
~1 of TBS containing 5% BSA and 1% gelatin for 2 h, Ltnd 
then washed three times with TBS containing 2 mM 
CaCl,, 0.1% BSA and 0.05% Tween-20. Afterwards, 100 
~1 of various concentrations of protein S in the same 
buffer used for washing were added to the each well and 
incubated at room temperature for 2 h. After washing the 
wells with the same buffer, bound protein S was deter- 
mined by using polyclonal anti-protein S F(ab)’ coupled 
with peroxidase and tetramethylbenzidine at 405 nm as 
described above. The apparent dissociation constant (K,) 
of protein S and C4BP was determined using the double- 
reciprocal plot analysis [371. 
2.9. Binding assay of APC to protein S 
Microwells were coated with 100 ~1 of monoclonal 
anti-protein S-IgG (10 pg/ml), termed MFS-1 (which did 
not inhibit APC cofactor activity of protein S), in 0.1 M 
sodium bicarbonate buffer (pH 9.2). After incubating for 2 
h, the wells were blocked with TBS containing 5% BSA 
and 1% gelatin for 2 h, and then washed three times with 
TBS containing 2 mM CaCl,, 0.1% BSA and 0.05% 
Tween-20. After this, 100 ~1 of protein S solution (25 
pg/ml) was added to the wells and the preparations were 
incubated overnight at room temperature. After washing 
the wells with the same buffer used for washing, 100 ~1 of 
various concentrations of APC in TBS containing 2 mM 
CaCl,, 0.1% BSA and 0.05% Tween-20 were added to the 
wells followed by incubation for 2 h. After washing the 
wells three times with the same buffer, 100 ~1 of 200 PM 
of Glu-Pro-Arg-pNA in 0.05 M Tris-HCl (pH S.O>, 0.1 M 
CsCl and 2 mM CaCl,, were added to the wells followed 
by incubation at 37°C for 1 h. The absorbance of pNA 
released by APC was determined at 405 nm as described 
above. The apparent K, of APC and protein S was 
determined using the double-reciprocal plot analysis [37]. 
2.10. Binding assay of factor Xa to protein S 
Binding of factor Xa to protein S was assayed by a 
similar method employed to determine the binding of APC 
to protein S using factor Xa instead of APC. To the 
microwells coated with protein S via monoclonal anti-pro- 
tein S IgG (MFS-1, 10 pg/ml), 100 ~1 of various concen- 
trations of factor Xa in TBS containing 2 mM CaCl, , 
0.1% BSA and 0.05% Tween-20 were added to the wells 
followed by incubation for 2 h. After washing the wells 
three times with the same bufff:r, the activity of factor Xa 
bound to protein S in the we&s was determined by adding 
100 ~1 of 200 PM Bz-Be-Glu-Gly-Arg-pNA in TBS 
containing 2 mM CaCl, foBowed by incubation at 37°C 
for 30 min. The absorbance (of pNA released by factor Xa 
was determined at 405 nm, as described above. 
2. I I. Binding assay of protein S, prothrombin or aPMS- 
,factor Xu to biotinylated factor Vu in solution phase 
Biotinylated factor V or factor Va (3.2 nM final concen- 
tration) was incubated at room temperature for 30 min 
with various concentrations of protein S, prothrombin or 
aPMS-factor Xa in TBS containing 0.1% BSA and 2 mM 
CaCl,. The mixture was then transferred to streptavidin- 
coated microwells and incubated for 30 min. The wells 
were then washed with TBS containing 0.1% BSA and 2 
mM CaCl,. ‘The protein S, prothrombin or aPMS-factor 
>Ya bound -to factor V or factor Va was determined using 
pt:roxidase-conjugated polyclonal anti-protein S F(ab)2, 
ant-i-prothro rnbin F(ab)* or anti-factor X F(ab)’ (0.5 
pm/ml fin al concentration) and tetramethylbenzidine (0.1 
mg/ml) as described [30]. The apparent K, of protein S, 
prothrombirn or aPMS-factor Xa for factor Va was deter- 
mined using: the double-reciprocal plot analysis [37]. 
To exarrine the effect of factor Xa or prothrombin on 
the binding of protein S to factor Va in solution phase, a 
mixture of various concentrations of aPMS-factor Xa or 
prothrombin and protein S (7.9 nM final concentration) in 
TBS containing 0.1% BSA and 2 mM CaCl, was incu- 
bated with ‘oiotinylated factor Va (2.1 nM final concentra- 
tion) at room temperature for 30 min. The mixture was 
then trarrsferred to streptavidin-coated microwells. Protein 
S boudl to biotinylated factor Va via streptavidin-coated 
microwells was determined as described above. 
To assess the effect of protein S (rPSN or rPST) on the 
binding of prothrombin or aPMS-factor Xa to factor Va in 
solution phase, a mixture of various concentrations of 
protein S and prothrombin (70 nM final concentration) or 
aPMS-factor Xa (83 nM ) in TBS containing 0.1% BSA 
and 2 mM CaCl, was incubated at room temperature for 
30 min with biotinylated factor Va (3.6 nM final concen- 
tration). The mixture was then transfened to streptavidin- 
coated microwells. Prothrombin or aPMS-factor Xa bound 
to biotinylated factor Va via streptavidin-coated microw- 
ells was determined as described above. 
3. Results 
3.1. APC cofactor activity of rPSN and rPST 
rPSN prolonged the APTT of protein S- and C4BP-de- 
pleted plasma in a dose-dependent manner. The specific 
activity (ability to prolong the clotting time/antigen con- 
centration) of rPSN was almost the same as that of plasma 
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Fig. I. APC cofactor activity of plasma protein S, rPSN and rPST. 100 
PI of various concentrations of plasma protein S (A 1, rPSN (0) or rPST 
(0) was mixed with 100 ~1 of protein S- and C4BP-depleted plasma 
containing APTT reagent (Actin). After 5 min. 50 ~1 of 2.5 mM CaClz 
was added to the mixture and clotting time was measured. 
protein S. On the contrary, rPST did not prolong the 
clotting time indicating that rPST lacks cofactor activity 
for APC (Fig. 1). 
3.2. Binding of rPSN and rPST to fixed phospholipids 
To clarify the mechanism by which rPST loses its APC 
cofactor activity, some properties of protein S required for 
expression of the APC cofactor activity were investigated. 
First, the ability of rPST to bind to phospholipids (cepha- 
lin) fixed to microwells was compared with that of rPSN. 
Both rPST and rPSN almost equally bound to phospho- 
lipids in the presence of Ca2+ ions with apparent K, 
values of 4.4 . lo-’ M and 4.0 . 1 O- ‘M, respectively (data 
not shown). These K, values were similar to that reported 
previously [4]. In the absence of Ca2+ both rPSN and rPST 
did not bind to phospholipids. 
3.3. Binding of rPSN and rPST to fixed C4BP 
It is well-known that C4BP inhibits the APC cofactor 
activity of protein S. Thus, if rPST shows an increased 
affinity for C4BP it would indicate that this abnormal 
protein S has a reduced cofactor activity for APC. Previous 
study showed that patients with protein SToku\hima have 
normal levels of protein S-C4BP complex in their plasma, 
suggesting that the affinity of protein SToku\hima for C4BP 
is not different from that of the normal protein S. To 
corroborate this clinical data the ability of rPST to bind to 
C4BP fixed to microwells was compared with that of 
rPSN. Both rPSN and rPST bound equally to fixed C4BP 
with an apparent K, of 7.5 . 10m9 M (data not shown). 
The binding ability of these recombinant proteins was the 
same as that of plasma protein S fixed to microwells with 
an apparent K, of 2-10. lop9 M [12]. 
3.4. Binding of APC to rPSN and rPST 
To elucidate the mechanism by which rPST loses its 
cofactor activity for APC, the ability of protein S to bind 
to APC was investigated. To avoid a probable conforma- 
tional change of protein S by fixing directly to microwells, 
an assay in which protein S binds to microwells via 
monoclonal anti-protein S IgG, termed MFS-1 [25], was 
developed. This MFS-1 does not inhibit APC cofactor 
activity of protein S. The amounts of rPSN and rPST 
bound to the microwells were confirmed to be equal by 
using peroxidase-coupled polyclonal anti-protein S IgG. 
The amount of APC bound to rPSN or rPST in the wells 
was determined after incubating with various concentra- 
tions of APC. As shown in Fig. 2, while APC bound to 
rPSN in proportion to the concentration of APC with a K, 
of 3.5 . IO-‘M, it did not bind to rPST. 
3.5. EfSect of rPSN and rPST on the activation of pro- 
thrombin by factor Xa 
First, APC-independent anticoagulant activity of plasma 
protein S was investigated and then that of rPST and rPSN. 
The effect of plasma protein S on the factor Xa-catalyzed 
activation of prothrombin was determined in the presence 
or absence of phospholipids and in the presence of throm- 
bin-stimulated platelets. Plasma protein S did not affect the 
prothrombin activation by factor Xa alone or in the pres- 
ence of phospholipids, but inhibited the prothrombin acti- 
vation in the presence of platelets. The inhibitory effect of 
0 50 loo 150 200 250 
Concentration of APC (nM) 
Fig. 2. Binding of APC to rPSN and rPST. rPSN (0) or rPST (0) was 
added to microplate wells coated with monoclonal anti-protein S IgG 
(MFS-I). After washing, 100 /*I of various concentrations of APC were 
added. APC bound to protein S was then determined using Glu-Pro-Arg- 
pNA (S-2366). 
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Fig. 3. Effect of protein S on the prothrombin activation by factor Xa. In 
the assay system using platelet-prothrombinase complex, various concen- 
trations of plasma protein S (A), rPSN (0) or rPST (0) were added. 
The generated thrombin was determined fluorescence spectrophotometri- 
tally using Boc-Val-Pro-Arg-MCA. Details of the experimental condi- 
tions are described under Section 2. 
rPSN and rPST on the factor Xa-catalyzed activation of 
prothrombin was then investigated using thrombin-stimu- 
lated platelets. As shown in Fig. 3, while rPSN and plasma 
protein S inhibited the prothrombin activation by platelet 
prothrombinase complex, rPST did not show this in- 
hibitory activity. 
3.6. Binding offactor Xa to protein S 
To clarify the mechanism by which protein S inhibits 
the platelet-prothrombinase complex activity, we first de- 
termined the effect of protein S on the amidolytic activity 
of factor Xa in solution phase. Protein S has been reported 
previously to inhibit the amidolytic activity of factor Xa 
[7]. However, in this investigation neither plasma protein S 
nor rPSN inhibited the amidolytic activity of factor Xa in 
solution phase (data not shown). The direct binding of 
factor Xa to protein S bound to monoclonal anti-protein S 
antibody (MFS-1) coated on microplate wells was also 
investigated. The amount of factor Xa bound to protein S 
was measured by the amidolytic activity of factor Xa. As 
shown in Fig. 4, factor Xa bound strongly to rPSN fixed to 
microwells with a K, of approx. 7 . 10m8 M, whereas 
factor Xa bound only slightly to rPST. Binding of factor 
Xa to rPSN was inhibited by DIP-APC in a dose-depen- 
dent manner. 
3.7. Binding of protein S to biotinylated factor Va in 
solution phase 
Protein S has been reported to bind to factor Va and this 
binding was suggested to be the mechanism by which 
protein S inhibits the prothrombinase complex activity [S]. 
Assessment of the way in which protein S binds to factor 
Va fixed directly to microwells disclosed little binding 
ability of protein S to fixed factor Va. The binding of 
protein S to factor Va was investigated using biotinylated 
factor V in solution phase. Protein S bound to biotinylated 
factor Va and factor V significantly and in a dose-depen- 
dent manner. The binding ability of protein S to factor Va 
was approx. 4-fold higher than that to factor V. This 
finding is in agreement with that previously reported by 
Heeb et al. [8]. Comparison of the bindings of rPSN and 
rPST to biotinylated factor Va in solution phase showed no 
significant differences between these two types of protein 
S (data not shown). On the other hand, binding of protein 
S (both plasma protein S and rPSN) to biotinylated factor 
Va in solution phase was not inhibited by factor Xa or by 
prothrombin even at concentrations of 2.50 nM and 500 
nM, respectively (data not shown). 
3.8. Effect of protein S on the binding of prothrombin or 
aPMS-factor Xa to biotinylated factor Va in solution phase 
To further investigate the mechanism by which the 
platelet-prothrombinase complex activity is inhibited by 
protein S, an assay system was developed to determine the 
binding of prothrombin or aPMS-factor Xa to biotinylated 
factor Va in solution phase. The effect of protein S on the 
binding of prothrombin or aPMS-factor Xa to biotinylated 
factor Va was examined. In this assay, prothrombin bound 
in a dose-dependent manner but weakly to biotinylated 
factor Va with an apparent K, of 5.5 . lo-‘M. This 
binding was not inhibited by either aPMS-factor Xa or 
protein S even at concentrations of 500 nM (data not 
0 50 100 150 200 
Concentration of factor Xa (nM) 
Fig. 4. Binding of factor Xa to rPSN and rPST. 100 ~1 of various 
concentrations of factor Xa was added to microwells fixed with rPSN 
(0) or rPST (0). Then, the bound factor Xa was determined spectropho- 
tometrically using Bz-Ile-Glu-Gly-Arg-pNA. Details of the experimental 
conditions are described under Section 2. 
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Fig. 5. (A) Binding of aPMS-factor Xa to biotinylated factor Va in 
solution phase in the presence or absence of phospholipids. 100 /.LI of 
various concentrations of aPMS-factor Xa was incubated with biotinyl- 
ated factor Va (3.6 nM) in solution phase in the presence (A ) or absence 
(A) of phospholipids. A complex of aPMS-factor Xa and biotinylated 
factor Va was then fixed to streptavidin-coated microwells. Bound 
aPMS-factor Xa was determined using peroxidase-coupled anti-factor X 
F(ab)’ as described under Section 2. (B) Effect of various concentrations 
of rPSN t 0) and rPST (a) on the binding of aPMS-factor Xa (10.4 nM) 
to biotinylated factor Va (3.6 nM) in solution phase in the presence of 
phospholipids. Bound aPMS-factor Xa to biotinylated factor Va was 
determined as described above. 
shown). On the other hand, aPMS-factor Xa bound signifi- 
cantly to biotinylated factor Va in solution phase, this 
binding being stronger in the presence of phospholipids 
(cephalin) (Fig. 5A). aPMS-factor Xa also bound to the 
biotinylated light chain of factor Va (data not shown). The 
effect of rPSN and rPST on the binding of aPMS-factor Xa 
to biotinylated factor Va was also determined. As shown in 
Fig. 5B, rPSN seems to cause an increase in the binding of 
aPMS-factor Xa to biotinylated factor Va rather than an 
inhibition of it. This phenomenon was not observed when 
rPST was used in the assay. 
4. Discussion 
The missense mutation (Lysi5” * Glu) in the second 
EGF domain of protein S (protein STokushima) found in 
patients with familial thrombosis was the first innate dys- 
functional protein S reported in literature [24,25]. In the 
present study, we compared several functional properties 
of protein STokurhima with those of normal protein S in 
relation to the molecular interactions of protein S required 
for the expression of cofactor activity of APC and for the 
inhibition of prothrombinase complex activity. Experi- 
ments were carried out using recombinant normal protein 
S, rPSN, and protein STokushimar rPST expressed in BHK 
cells. 
In the functional assays, rPST did not show either APC 
cofactor activity or inhibitory activity against the pro- 
thrombinase complex activity. Results of the investigations 
on the molecular interactions of rPSN and rPST with 
phospholipids suggest that the Gla and the thrombin-sensi- 
tive domains of rPST present normal conformations [4,5]. 
These domains are probably required for the interaction of 
rPST with phospholipids. Moreover, the fact that rPST 
bound normally to solid phase C4BP suggests that the 
conformation of the binding sites of C4BP on rPST is 
conserved. This binding site is probably located in the 
COOH-terminal region of the SHBG domain. On the other 
hand, assays using solid phase rPST showed that, unlike 
rPSN, rPST has no ability to bind to APC. As it is 
well-known this binding is essential for the expression of 
the APC cofactor activity. Previous studies have shown 
that the region including the Gla domain through the first 
EGF domain of protein S is important for the expression of 
the APC cofactor activity [5,18]. Based on the results of 
the present study, the second EGF domain seems to be also 
crucial for the binding of protein S to APC. However, it is 
unclear whether the site for direct interaction with APC is 
located in this domain of protein S. The fact that factor Va 
failed to inhibit the APC binding to protein S supports 
previous reports that factor Va interacts with the COOH- 
terminal region of protein S [21]. On this basis, we specu- 
late that APC interacts with the NH,-terminal region of 
protein S and catalyzes factor Va bound to the COOH- 
terminal region of protein S. 
On the other hand, the molecular mechanism by which 
protein S inhibits the prothrombinase complex activity and 
that by which protein STokuahima fails to show the same 
effect are more complicated. As reported previously [7], 
we found that protein S exhibits inhibitory effect on the 
prothrombin activation by factor Xa in the presence of 
factor Va in the platelet prothrombinase system. In this 
system, rPSN and plasma protein S inhibited the prothrom- 
binase complex activity, but not rPST. Namely, protein 
S rokushima lacks APC-independent anticoagulant activity. 
Although no direct inhibition of the amidolytic activity of 
factor Xa by protein S was observed, factor Xa bound 
directly to rPSN and to plasma protein S fixed to microw- 
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ells via monoclonal anti-protein S antibody immobilized 
on microplate wells. However, factor Xa did not bind to 
rPST. This finding may partially explain the lack of in- 
hibitory activity of rPST against the platelet-pro- 
thrombinase complex activity. 
We also investigated the way in which protein S binds 
to factor Va and factor V in solution phase using biotinyl- 
ated factor Va and V. Protein S bound weakly to solid- 
phase factor Va (V) due probably to the occurrence of 
conformational change in the factor Va (V) fixed to mi- 
crowells. Comparing the bindings of rPST and rPSN to 
factor Va, the binding ability of rPST to biotinylated factor 
Va was only slightly less than that of rPSN (80-90% of 
the binding of rPSN). Further, the binding of protein S to 
biotinylated factor Va was not inhibited either by factor Xa 
or by prothrombin. These findings suggest that the loss of 
the inhibitory activity of rPST against the platelet-pro- 
thrombinase complex does not depend on the interaction 
between rPST and factor Va. Moreover, the fact that 
prothrombin binding to factor Va was not inhibited by 
aPMS-factor Xa, DIP-APC or protein S, suggest that the 
binding site of prothrombin on factor Va differs from that 
of factor Xa, APC and protein S. 
To elucidate whether or not protein S blocks directly 
the interaction between factor Xa and factor Va, we used a 
solution-phase binding assay and found that, rather an 
inhibition, rPSN provokes an increase in the binding of 
factor Xa to factor Va. This phenomenon was not observed 
when rPST (which does not bind to factor Xa) was used. 
Based on this, we conjecture that rPSN forms probably a 
ternary complex with factor Xa and factor Va and, in this 
way, it reduces the likelihood of any direct interaction of 
factor Xa with factor Va due to the interposition of rPSN 
between these two clotting factor molecules. This may 
eventually lead to an inhibition of the prothrombinase 
complex activity. Accordingly, the lacks of the inhibitory 
effect of rPST on the platelet-prothrombinase complex 
activity occurs probably because this abnormal protein S is 
unable to interact with factor Xa. 
Based on these results, we suggest that substitution of 
Lys 155 for Glu in the second EGF domain of protein S 
does not affect the molecular interactions of protein S with 
C4BP, factor Va and prothrombin, but does affect its 
interaction with APC and factor Xa. The molecular mecha- 
nism by which protein SToku\h,ma fails to bind to APC and 
factor Xa needs further investigation. The results of the 
present study are compatible with previously reported ob- 
servations: a mini protein S with deletion of its SHBG 
domain showed a full APC cofactor activity and a partial 
inhibitory effect on the prothrombinase complex activity 
[38], the inability of APC to bind to reduced protein S [ 121, 
the binding of C4BP to region involving residual Ser4*‘- 
Leu435 [ 191 and Gly604-Ile6’4 [20] and the binding of factor 
Va to region involving residues Arg62’-Ser635 of the 
COOH-terminal end [2 11. The LYS’~~ residue of the second 
EGF domain is conserved in the protein S of humans 
[ 13,141, bovine [ 151, mice [39] and rats [17], but not in that 
of rabbits [16], suggesting that the region involving this 
residue is important for the expression of the function of 
protein S. Based on these data the following conclusions 
can be outlined: (1) protein S enhances the relationship 
between APC and factor Va required for the expression of 
the APC-dependent anticoagulant activity; (2) protein S 
blocks the direct interaction of factor Xa, but not that of 
prothrombin [6], with factor Va required for the inhibition 
of the prothrombinase complex activity in the APC-inde- 
pendent anticoagulant activity; and (3) the second EGF 
domain of protein S is crucial for the binding of both APC 
and factor Xa as inferred from the molecular abnormality 
found in the second EGF domain of protein STokushima. 
Recently, factor V but not factor Va was proposed to 
play a role as a cofactor for APC by acting synergistically 
with protein S in the degradation of factor VIIIa [40]. 
However, we found no abnormality of protein STokuahima in 
this reaction. 
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